Profile
Martin Bott served as the VP-Corporate Finance & Investment Banking at Eli Lilly & Co. from 2015 to 2017.
He also served as an Independent Director at InMed Pharmaceuticals, Inc. from 2017 to 2019 and as a Director at CoLucid Pharmaceuticals, Inc. Additionally, he received an undergraduate degree from Universität zu Köln in 1985 and a graduate degree from the University of South Carolina in 1988.
Former positions of Martin Bott
Companies | Position | End |
---|---|---|
INMED PHARMACEUTICALS INC. | Director/Board Member | 31/08/2019 |
ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/12/2017 |
COLUCID PHARMACEUTICALS INC | Director/Board Member | - |
Training of Martin Bott
Universität zu Köln | Undergraduate Degree |
University of South Carolina | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
INMED PHARMACEUTICALS INC. | Health Technology |
Private companies | 1 |
---|---|
CoLucid Pharmaceuticals, Inc.
CoLucid Pharmaceuticals, Inc. BiotechnologyHealth Technology CoLucid Pharmaceuticals, Inc. engaged in the development of therapeutics for neurological disorders. Its products included Lasmiditan, a neurally acting anti-migraine agent that is designed to delivered efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies and a Conjugated Stigmines platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. The company was founded by James F. White and Arthur M. Pappas in 2005 and was headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Martin Bott